Management of Cardiogenic Shock

Initial Management

• The European Society of Cardiology recommends that in cardiogenic shock, inotropes (dobutamine, dopamine, or phosphodiesterase III inhibitors) are the first-line agents, with norepinephrine added only when persistent hypotension remains despite inotropic therapy and fluid resuscitation 1, 2
• Dobutamine is the recommended first-line agent for cardiogenic shock to increase cardiac output in patients with poor myocardial function 1, 2, 3
• Dopamine may be considered specifically in patients with bradycardia or low risk for tachycardia 1, 2

Vasopressor Use

• Norepinephrine should be added only when the combination of inotropic therapy and fluid challenge fails to restore systolic blood pressure >90 mmHg with persistent signs of inadequate organ perfusion 1, 2, 3
• Norepinephrine is the preferred vasopressor when blood pressure support is needed 1, 2

Alternative Agents

• Levosimendan may be considered as an alternative or additional agent when dobutamine fails to restore adequate perfusion 3
• Vasopressin may be added to reduce norepinephrine requirements at doses up to 0.03 units/min 1, 2

Monitoring

• The American Heart Association recommends monitoring hemodynamic targets, including systolic blood pressure >90 mmHg 3 and mean arterial pressure ≥65 mmHg 1
• Perfusion markers, such as urine output, serum lactate clearance, mixed or central venous oxygen saturation, mental status, and skin perfusion, should be assessed serially 1, 2, 4, 5

Common Pitfalls

• The European Society of Intensive Care Medicine advises against using vasopressors as first-line agents, and instead recommends optimizing volume status and initiating inotropes first 1, 2, 3
• All vasopressors should be discontinued as soon as possible due to their propensity to increase myocardial oxygen demand and risk of arrhythmias 1, 2, 3

Norepinephrine Dosing for Cardiogenic Shock

Introduction to Norepinephrine Use

• The European Society of Cardiology recommends norepinephrine initiation at 0.2-1 mcg/kg/min when inotropic therapy and fluid resuscitation fail to restore systolic blood pressure >90 mmHg with persistent signs of inadequate organ perfusion, and should be used with extreme caution as a second-line agent only 6, 7, 8

Algorithmic Approach to Vasopressor Use

• The European Society of Cardiology suggests optimizing volume status with fluid challenge (250 mL over 10 minutes if clinically indicated) before adding norepinephrine 6, 7
• Norepinephrine should only be added when inotropic therapy plus fluid challenge has failed to restore adequate blood pressure, with systolic blood pressure remaining <90 mmHg 6, 7

Norepinephrine Dosing and Administration

• The European Heart Journal recommends an initial norepinephrine dose of 0.2-1 mcg/kg/min 8
• The European Society of Cardiology advises administering norepinephrine through a central line ideally to avoid tissue necrosis from extravasation 6

Critical Pitfalls to Avoid

• The European Society of Cardiology explicitly contraindicates using vasopressors as first-line agents, as this can increase afterload on an already failing heart, potentially worsening cardiac output and end-organ perfusion 6, 7, 8

Alternative Considerations

• The European Society of Cardiology suggests evaluating for mechanical circulatory support (IABP, ventricular assist devices) as vasopressors are only a bridge therapy 6, 7